Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 852 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
ORIGINAL ARTICLE
Year : 2011  |  Volume : 15  |  Issue : 5  |  Page : 33-39

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes


1 Department of Pharmacology, Government Medical College, Miraj, Maharashtra, India
2 Department of Pharmacology, R.C.S.M. Government Medical College, Kolhapur, Maharashtra, India
3 Director, Patwardhan Endocrinology Hospital and Research Centre, Miraj, Maharashtra, India

Correspondence Address:
Karuna Balwant Ramteke
Department of Pharmacology, Government Medical College, Miraj, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.83062

Rights and Permissions

Context: Diabetes mellitus is a chronic metabolic disorder of endocrinal origin with multiorgan involement. Today's physician has a lot many options to choose for treating type 2 diabetes, but does not always manages to achieve optimal glycemic control. The newer drug bromocriptine acts by novel hypothalamic circadian rhythm resetting mechanism. Objective: To evaluate the efficacy and safety of bromocriptine QR in type 2 diabetes. Materials and Methods: 105 patients according to inclusion and exclusion criteria were randomized into three groups by simple randomization. Group 1 received bromocriprine 2.4 mg once daily, group 2 received metformin 500 mg twice daily while group 3 received bromocriprine 1.6 mg daily and metformin 500 mg twice daily. Baseline measurement of fasting and postprandial blood sugar, HbA1 C and BMI were followed up at 6 th and 12 th weeks. Safety evaluation was done by questioning the patient and also through routine hematological and biochemical parameters. Z test was used for analysis. Results: Group 1 showed significant reduction in fasting and postprandial sugar and HbA 1c at 12 weeks. While groups 2 and 3 showed even higher reduction in these parameters albeit with slightly more adverse drug events like nausea, vomiting compared to group 1. Conclusion: Bromocriptine QR is an effective and safe antidiabetic drug which can be employed as monotherapy or in conjuction with metformin to achieve and maintain optimal glycemic control.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2747    
    Printed65    
    Emailed1    
    PDF Downloaded555    
    Comments [Add]    
    Cited by others 5    

Recommend this journal